Witryna1 wrz 2024 · In 2024, pembrolizumab became the first immunotherapy agent approved to treat stomach cancer in some patients whose treatment did not work or stopped working (≥2 lines). Ongoing randomized trials will be expected to confirm immunotherapy as a validated therapeutic option for AGC, especially in neoadjuvant … Witryna12 kwi 2024 · Unfortunately, the vast majority of hepatocellular carcinoma patients suffer from advanced unresectable or metastatic disease at diagnosis. Currently targeted therapy alone, or in combination with anti-vascular endothelial growth factor antagonist, is the standard first-line treatment for metastatic hepatocellular carcinoma.
FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric Cancer
Witryna12 kwi 2024 · Gastric carcinoma (GC) is the 2nd most common cause of cancer-related death. Despite advances in conventional treatment and surgical interventions, a high percentage of GC patients still have poor survival. Recently, immunotherapy has become a promising approach to treat GC. Here, we present preclinical and clinical … Witryna17 lis 2024 · Gastric cancer, the fifth most frequent cancer and the fourth leading cause of cancer deaths, accounts for a devastating death rate worldwide. Since the majority … crystal cave company
Neoadjuvant therapy strategies for advanced gastric cancer: …
WitrynaOur treatments include targeted therapy, immunotherapy, chemotherapy, advanced radiation therapy and state-of-the-art surgery. A stomach cancer patient’s treatment … WitrynaThe combination of nivolumab and sunitinib in advanced sarcoma has been studied by the phase I/II trial IMMUNOSARC, including 40 patients with BS and 50 patients with STS. In the BS cohort, there was 1 CR (2.5%), 1 PR (2.5%) and 22 SD (55%) among 40 assessable patients, with a median PFS of 3.7 months [ 100 ]. WitrynaEfficacy was evaluated in CHECKMATE-649 (NCT02872116), a randomized, multicenter, open-label trial that enrolled 1,581 patients with previously untreated advanced or … crystal cave dnd